These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Arterial hypertension and renal vascular disease: nephroangiosclerosis]. Marín R; Gorostidi M; Pobes A Nefrologia; 2002; 22 Suppl 1():36-45. PubMed ID: 11987669 [TBL] [Abstract][Full Text] [Related]
4. Systemic and glomerular hypertension and progression of chronic renal disease: the dilemma of nephrosclerosis. Marín R; Gorostidi M; Fernández-Vega F; Alvarez-Navascués R Kidney Int Suppl; 2005 Dec; (99):S52-6. PubMed ID: 16336577 [TBL] [Abstract][Full Text] [Related]
5. Dyslipidemia and hypertension: twin killers in renal vascular disease. Zuccalà A Am J Kidney Dis; 2001 Jun; 37(6):1319-23. PubMed ID: 11382708 [No Abstract] [Full Text] [Related]
6. (8) Cardiovascular disease and risk management. American Diabetes Association Diabetes Care; 2015 Jan; 38 Suppl():S49-57. PubMed ID: 25537708 [No Abstract] [Full Text] [Related]
7. Antihypertensive therapy and atherosclerosis. Horan MJ Am J Med Sci; 1991 Jun; 301(6):402-5. PubMed ID: 2039028 [TBL] [Abstract][Full Text] [Related]
8. Hypertension and atherosclerosis. Ram CV Prim Care; 1991 Sep; 18(3):559-75. PubMed ID: 1946788 [TBL] [Abstract][Full Text] [Related]
9. [Nephroangiosclerosis or hypertensive nephropathy]. del Río Vázquez A Rev Clin Esp; 1994 Aug; 194(8):620-2. PubMed ID: 7938843 [No Abstract] [Full Text] [Related]
10. Antiplatelet activity of drugs used in hypertension, dyslipidemia and diabetes: Additional benefit in cardiovascular diseases prevention. Sepúlveda C; Palomo I; Fuentes E Vascul Pharmacol; 2017 Apr; 91():10-17. PubMed ID: 28342822 [TBL] [Abstract][Full Text] [Related]
11. Enhanced atherosclerosis and kidney dysfunction in eNOS(-/-)Apoe(-/-) mice are ameliorated by enalapril treatment. Knowles JW; Reddick RL; Jennette JC; Shesely EG; Smithies O; Maeda N J Clin Invest; 2000 Feb; 105(4):451-8. PubMed ID: 10683374 [TBL] [Abstract][Full Text] [Related]
12. [Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment]. Cases Amenós A; Goicoechea Diezhandiño M; de Alvaro Moreno F Nefrologia; 2008; 28 Suppl 3():39-48. PubMed ID: 19018737 [TBL] [Abstract][Full Text] [Related]
13. Hypertension, plasma lipids and antihypertensive drugs. Kesäniemi YA; Lilja M Ann Med; 1991 Aug; 23(3):347-51. PubMed ID: 1930928 [TBL] [Abstract][Full Text] [Related]
14. The kidney as part of the cardiovascular system. Ruilope LM J Cardiovasc Pharmacol; 1999; 33 Suppl 1():S7-10; discussion S41-3. PubMed ID: 10028947 [TBL] [Abstract][Full Text] [Related]
15. [Nephroangiosclerosis and ischemic nephropathy: two different entities or two renal manifestations of the same systemic cardiovascular disease?]. Zuccala' A; Cianci R; Presta P; Fuiano G G Ital Nefrol; 2009; 26(3):299-309. PubMed ID: 19554527 [TBL] [Abstract][Full Text] [Related]
16. Recommendations for special populations: diabetes mellitus and the metabolic syndrome. Sowers JR Am J Hypertens; 2003 Nov; 16(11 Pt 2):41S-45S. PubMed ID: 14625160 [TBL] [Abstract][Full Text] [Related]